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(-40.2%, p = 0.0007) and fewer physician visits (-4.4%,
p = 0.0259), than those on SAL/FLU, after controlling for base-
line characteristics. The BUD/FORM patients were less likely to
switch to an alternative ICS + LABA combination (OR = 0.58,
p = 0.0067). Numbers of hospitalisations, referrals and work
absences did not differ between groups. CONCLUSION: BUD/
FORM was associated with a lower probability of treatment
switches, fewer acute exacerbations, and with similar or lower
resource utilisation compared with SAL/FLU. Although the
groups appeared well matched at treatment initiation, these
results should be interpreted with caution given the observational
nature of this study.
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OBJECTIVES: EPR-2 guidelines were developed to improve
medication prescribing for patients with persistent asthma and to
control acute exacerbations of asthma. In addition these guide-
lines also encourage physician provided asthma education. Little
is known about prescribing adherence to EPR-2 guidelines. This
study examined physician adherence to EPR-2 asthma medica-
tion prescribing guidelines and determine patient and physician
factors associated with prescribing of asthma medications.
METHODS: This study was a cross-sectional retrospective
analysis of complex NAMCS physician visit survey data from
1998 through 2004. Data were extracted on all patient s with an
ICD-9 code for asthma (493.XX) and reason for visit as
‘asthma’. Unit of analysis was individual patient visit. Dependent
variables in analyses were speciﬁc type of drug class. Independent
variables were various patient and physician factors. Logis-
tic regression analysis was used to assess study objectives.
RESULTS: Asthma patients in 2002 were 3.3 times more likely to
be prescribed controller medications compared in 1998. Findings
in 2004 were not signiﬁcant. Elderly patients were 54% as likely
to receive controller medication compared to the 35–64 year age
group. Patients other than whites or African Americans are 40%
as likely to receive controller asthma medication compared
to whites. Physicians were 6.3 times more likely to prescribe
long acting beta agonists compared to 1998. Physicians without
ownership stake in their practice were 1.9 times more likely to
provide asthma education to their patients compared to those
who owned their practice. CONCLUSION: This study using US
outpatient setting data provides evidence that physician prescrib-
ing of asthma pharmacotherapy in the US does not adequately
comply with EPR-2 treatment guidelines.
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OBJECTIVES: Medical care costs for rhinitis are primarily
driven by patient care-seeking behavior and physician prescrib-
ing patterns, which may evolve over time. Estimating a model of
real-world rhinitis treatment from clinical trial data is not fea-
sible due to short trial durations and protocol-driven care. There-
fore, we used U.S. health care claims data to model rhinitis
treatment patterns and estimate the budgetary impact of a novel
rhinitis therapy. METHODS: We developed a three-year budget-
ary impact model of rhinitis using Markov-modeling techniques.
Transitions between treatment regimens (monotherapy, dual-
combination therapy, tri-combination therapy), treatment pat-
terns, (therapy switching, add-on rates), and associated medical-
care costs, were estimated from a large claims database, by
identifying rhinitis patients and tracking changes in therapy over
time. Budgetary impact of a novel treatment was assessed for
three effectiveness scenarios, where the switching/add-on rates
relative to ﬂuticasone propionate, an existing rhinitis therapy,
were 50% lower (Scenario 1), 25% lower (Scenario 2) and
identical (Scenario 3). The novel treatment was assumed to be
priced the same as ﬂuticasone propionate and have a market
share of 10%. RESULTS: The claims analysis found annual rates
of treatment switching, add-on, and remaining on initial therapy
ranging from 6–18%, 20–28%, and 62–72%, respectively,
for currently existing rhinitis therapies. Annual rhinitis-related
medical costs associated with each treatment pattern were $666,
$657, and $558, respectively. In Scenario 1, the model predicted
the per-patient-per-month (PPPM) budgetary impact for the
novel treatment to be -$0.06, -$0.09, and -$0.11, in years 1–3,
respectively. Scenarios 2 and 3 had corresponding PPPM results
of $0.00, -$0.01, and -$0.01, and $0.05, $0.06, $0.08. CON-
CLUSION: Using claims data and Markov-modeling techniques,
we found that budgetary impact can be materially affected by
rates of treatment switching/add-on. Detailed, claims-based data
are required for this type of analysis, given the real-world nature
of treatment patterns and associated medical costs.
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OBJECTIVES: We hypothesized that the average medication
possession ratio (MPR) for controller medications in adult asth-
matic populations may be misleading as a basis for evaluating
adherence. METHODS: MPR distributions were determined
from analysis of the Pharmetrics database for the period April
2004 to March 2005. We assessed MPRs for those plan members
exclusively on one of the three major controller medication
groups: inhaled corticosteroids, combined inhaled corticoster-
oids and long acting beta agonists, and leukotriene modiﬁers.
MPR were deﬁned in terms of annual days supplied (range 0 to
1.0). RESULTS: Overall, for the study population (n = 17,581)
5,806 were exclusively on combination therapy (33.8%), 2,689
were exclusively on leukotriene modiﬁers (15.3%) and 2,106
exclusively on inhaled corticosteroids (12.0%). Average (median)
MPRs were 0.51 (0.57) for combination therapy; 0.55 (0.63) for
leukotriene modiﬁers; and 0.39 (0.33) for inhaled corticoster-
oids. Distributions of MPRs for these groups showed signiﬁcant
bi-modality (a “U” shaped MPR proﬁle). This characteristic was
most pronounced for the combined controller group medications
and the leukotriene modiﬁers where the frequency distributions
were almost identical. For the combined medications 32.2% of
adults reported a MPR < 0.2, with 19.0% and 28.9% reporting
MPRs of 0.6 to 0.79 and 0.8 to 1.0 respectively. The correspond-
ing estimates for leukotriene modiﬁers were 27.5%, 19.6%
and 33.1% respectively. For inhaled corticosteroids, 45.2% of
patients reported an MPR < 0.2 with only 33.2% reporting an
MPR > 0.6 (15.5% > 0.8). CONCLUSION: This analysis con-
ﬁrms the hypothesis that average MPR may be a misleading
indicator of adherence in patients taking combined controller
medications and leukotriene modiﬁers. We suggest an approach
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